Citi Maintains a 'Buy' on Genzyme (GENZ); Manufacturing Saga Continues- Cerezyme On Track, But Fabrazyme Lost
Tweet Send to a Friend
Citi maintains a 'Buy' on Genzyme Corp (Nasdaq: GENZ), lowers price target from $66 to $64.
Citi analyst says, "Genzyme ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Citi analyst says, "Genzyme ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
